Drugs Xagena
Despite the lack of evidence for its safety and effectiveness, many doctors believe the practice of giving patients with sudden ST-elevation myocardial infarction drugs before undergoing emergency revascularisation procedures ( angioplasty or stent placement ) improves outcome.
However, preliminary studies have suggested this practice confers no benefit.
To investigate the effect of pre-intervention drug treatment, Ellen Keeley ( University of Texas Southwestern Medical Center, Dallas ) and colleagues reviewed data from 17 trials comparing the outcomes for ST-elevation heart attack patients assigned the drug based procedure before angioplasty/stent placement ( 2237 ) and those assigned angioplasty/stent placement alone ( 2267 ).
The investigators found that more of the patients who received drugs prior to their intervention died than those who did not receive medication ( 106 versus 78 ).
Pre-intervention drugs also increased the risk of non-fatal myocardial infarction, bleeding, stroke, and the need for repeat revascularisation treatment. These increased rates were mainly seen when the pharmacological treatment was a drug that dissolved clots ( thrombolytic therapy ).
Keeley states: " Drug facilitated angioplasty or stent placement offers no benefit over primary intervention in ST-elevation heart attack and should not be used outside the context of randomised controlled trials. Furthermore facilitated interventions with thrombolytic-based regimens should be avoided."
In an accompanying Comment Gregg Stone ( Columbia University Medical Center and the Cardiovascular Research Foundation, New York ) and Bernard Gersh ( Mayo Clinic, Rochester ) state: " The results of this quantitative review are unequivocal and surprising: facilitated angioplasty compared with primary angioplasty alone, rather than saving lives as expected, results in an increase in mortality, along with greater rates of reinfarction, urgent repeat revascularisation, major bleeding, haemorrhagic stroke, and total stroke."
In a different trial ( ASSENT-4 ), also published by The Lancet, FransVan de Werf ( Gasthuisberg University Hospital, Leuven, Belgium ) and colleagues looked at whether giving patients with ST-elevation heart attack the drug Tenecteplase ( TNKase/ Metalyse ) before a delayed angioplasty/stent placement would result in a better outcome than those receiving the delayed procedure alone.
They found that a strategy of full-dose Tenecteplase was associated with major adverse events when compared with angioplasty/stent placement alone and cannot be recommended.
Source: The Lancet, 2006
XagenaMedicine_2006
